Sutro Biopharma Inc
NASDAQ:STRO
Sutro Biopharma Inc
NASDAQ:STRO
Price:
25.43
USD
1.8%
Market Closed
Market Cap:
$410.3m
Balance Sheet
Balance Sheet Decomposition
Sutro Biopharma Inc
Sutro Biopharma Inc
Balance Sheet Decomposition is not available for
Sutro Biopharma Inc
Sutro Biopharma Inc
Balance Sheet
Sutro Biopharma Inc
Sutro Biopharma Inc
Currency: USD
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
12
|
22
|
125
|
5
|
206
|
30
|
47
|
69
|
190
|
|
| Cash Equivalents |
12
|
22
|
125
|
5
|
206
|
30
|
47
|
69
|
190
|
|
| Short-Term Investments |
36
|
0
|
79
|
113
|
162
|
168
|
287
|
306
|
127
|
|
| Total Receivables |
1
|
2
|
3
|
6
|
6
|
13
|
7
|
36
|
9
|
|
| Accounts Receivables |
1
|
2
|
3
|
6
|
6
|
13
|
7
|
36
|
9
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
2
|
2
|
3
|
4
|
5
|
8
|
12
|
10
|
18
|
|
| Total Current Assets |
50
|
26
|
210
|
129
|
378
|
219
|
353
|
422
|
343
|
|
| PP&E Net |
19
|
14
|
11
|
10
|
13
|
52
|
51
|
45
|
36
|
|
| PP&E Gross |
19
|
14
|
11
|
10
|
13
|
52
|
51
|
45
|
36
|
|
| Accumulated Depreciation |
20
|
25
|
29
|
34
|
37
|
33
|
38
|
42
|
49
|
|
| Long-Term Investments |
0
|
0
|
0
|
16
|
0
|
69
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
1
|
1
|
2
|
3
|
3
|
3
|
3
|
4
|
8
|
|
| Total Assets |
69
N/A
|
41
-41%
|
223
+447%
|
156
-30%
|
394
+152%
|
341
-13%
|
407
+19%
|
471
+16%
|
387
-18%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
3
|
3
|
3
|
6
|
6
|
11
|
5
|
9
|
10
|
|
| Accrued Liabilities |
3
|
4
|
6
|
6
|
9
|
13
|
33
|
60
|
52
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
15
|
5
|
1
|
0
|
9
|
13
|
4
|
0
|
|
| Other Current Liabilities |
44
|
11
|
22
|
20
|
15
|
9
|
17
|
21
|
70
|
|
| Total Current Liabilities |
50
|
32
|
36
|
33
|
30
|
42
|
67
|
94
|
132
|
|
| Long-Term Debt |
1
|
2
|
10
|
9
|
25
|
16
|
4
|
0
|
0
|
|
| Other Liabilities |
6
|
14
|
45
|
17
|
8
|
31
|
120
|
227
|
211
|
|
| Total Liabilities |
58
N/A
|
47
-18%
|
92
+94%
|
59
-36%
|
62
+6%
|
89
+43%
|
190
+114%
|
321
+69%
|
343
+7%
|
|
| Equity | ||||||||||
| Common Stock |
103
|
103
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
95
|
115
|
150
|
196
|
228
|
333
|
453
|
559
|
787
|
|
| Additional Paid In Capital |
5
|
6
|
282
|
293
|
560
|
586
|
670
|
709
|
831
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Total Equity |
12
N/A
|
7
N/A
|
132
N/A
|
98
-26%
|
332
+239%
|
253
-24%
|
217
-14%
|
150
-31%
|
45
-70%
|
|
| Total Liabilities & Equity |
69
N/A
|
41
-41%
|
223
+447%
|
156
-30%
|
394
+152%
|
341
-13%
|
407
+19%
|
471
+16%
|
387
-18%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
2
|
2
|
2
|
2
|
5
|
5
|
6
|
6
|
8
|
|
Switch to:
Switch to:
See Also
Discover More
